ÂÜŔňÂŇÂ×

Michael Rosenblatt, M.D., serves as the Chief Medical Officer of Flagship Pioneering. Prior to this role, Dr. Rosenblatt was the Executive Vice President and Chief Medical Officer for Merck from 2009 until 2016. He also served as Dean of Tufts University School of Medicine, and held appointments as the Robert Ebert Professor of Molecular Medicine and then George R. Minot Professor of Medicine at Harvard Medical School. He was a scientific founder of ProScript, the company that discovered bortezomib (Velcade), now Millennium Pharmaceutical’s drug for multiple myeloma and other malignancies, and Radius Pharmaceuticals, a women’s health company. Dr. Rosenblatt is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck. He serves as a member of the Board of Directors for Ferring Pharmaceuticals (U.S. Division), Rubius Therapeutics, Brooks Automation and several early stage biotech companies. Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency and endocrinology training were all at the Massachusetts General Hospital.